Opendata, web and dolomites

GlyCan

Innovative Glycan-based analysis for Cancer diagnostics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GlyCan project word cloud

Explore the words cloud of the GlyCan project. It provides you a very rough idea of what is the project "GlyCan" about.

dre    representing    mistreatment    check    b2b    needless    discriminates    366k    clinics    glycan    mrna    sick    diagnostic    biomarker    quantify    biomolecules    owned    worldwide    proteins    founder    tkac    business    covered    protein    undergo    market    commercial    hospital    antigen    confirm    grant    throughput    societal    invasive    rate    pca    accurately    biopsy    serum    ing    pain    granted    biopsies    digital    2nd    lacks    rectal    team    74    core    blood    examinations    b2c    home    jan    dx    accuracy    quantifying    patent    assay    annually    examination    311532    consists    company    centres    kit    competitors    simplicity    sending    advisors    screening    epo    prostate    dna    95    erc    circulating    members    cancer    combined    economic    detect    launched    healthy    psa    burden    competitive    glycanostics    false    clinically    preliminary    outcome    advantage    prior    opinion    deaths    6m    dr    positive    patients    scientific    cso    innovative    suspicious    diagnostics    75    biomarkers    co    homes    instead   

Project "GlyCan" data sheet

The following table provides information about the project.

Coordinator
GLYCANOSTICS SRO 

Organization address
address: DUBRAVSKA CESTA 9
city: BRATISLAVA
postcode: 845 38
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Slovakia [SK]
 Project website https://www.glycanostics.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLYCANOSTICS SRO SK (BRATISLAVA) coordinator 50˙000.00

Map

 Project objective

Worldwide, there are 1.6M new prostate cancer (PCa) cases with 366k deaths annually. Novel PCa biomarkers are needed since the best current PCa biomarker (prostate specific antigen (PSA)) lacks PCa diagnostic accuracy often resulting in mistreatment of PCa patients. The false-positive rate of PSA in blood serum is ~75%. PSA test is applied together with digital rectal examination (DRE) for preliminary screening. If the combined results are suspicious, the patients undergo a biopsy to confirm PCa. Yet, there are 74% of needless biopsies representing a significant pain for PCa patients and societal/economic burden.

Based on a great commercial outcome from the ERC grant (311532) granted to Dr. Jan Tkac (co-founder/CSO of Glycanostics), the company has developed an innovative, non-invasive, early PCa diagnostics using blood serum. Instead of quantifying PSA, the innovative PCa diagnostic assay detect glycan changes on PSA protein (it discriminates between “healthy” PSA and “sick” PSA and accurately quantify the clinically relevant “sick” PSA). The technology is covered by two EPO patent applications owned by the company. The PCa diagnostic test with 95% accuracy will be applied as a 2nd opinion test in case of suspicious results from PSA & DRE examinations prior sending to a biopsy. PCa DX kit will be launched for clinics/hospital & cancer centres (B2B) and Prostate check home test for user-friendly application at homes (B2C).

Our PCa diagnostic technology is unique compared to our competitors focusing on analysis of other complex biomolecules such as a level of proteins, mRNA and circulating DNA. Moreover, we have competitive advantage over competitors in terms of cost per sample, assay accuracy, simplicity of the assay enabling the home testing and high-throughput.

Glycanostics consists of 7 core team members, 4 business and 4 scientific advisors making a great and highly experienced team that will bring these innovative PCa early diagnostic products to the market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLYCAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLYCAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

DetectInMen (2019)

Infection detection in human semen

Read More  

Plasmanorg (2019)

Environmental-friendly organic chemical synthesis in plasma reactor

Read More